Company intelligence / Profile preview

Atea Pharmaceuticals

Boston, Massachusetts, United Statesateapharma.com ↗

Ownership: Public · AVIR
Development stage: Phase 2

Overview

Atea’s lead program combines bemnifosbuvir and ruzasvir as an all‑oral regimen targeting hepatitis C virus. The combination has completed Phase 2 studies with positive results and a Phase 3 trial was expected to begin enrollment in April 2025. Bemnifosbuvir has also been studied in COVID‑19 but the company’s primary focus now appears to be HCV. The company leverages its proprietary nucleos(t)ide prodrug platform to develop novel antivirals against ssRNA viruses.[1][3][4][7]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (specifically oral antiviral agents)Nucleos(t)ide analogs/prodrugs[3][7][9]
Industry: Biotech

Drug pipeline

6 assets

ruzasvir

5 more assets in the full pipeline.

Request access →

Partnerships

No major disclosed pharma partnerships currently; actively seeking strategic partnerships related to its Phase 3-ready HCV program as of late 2024.[9]

Financials

Market cap: $454.6M
Total revenue: $0
Enterprise value: $235.5M

Beyond the preview

Go deeper on Atea Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atea Pharmaceuticals.

Explore the full profile